MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Отворен

1.26 -3.08

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.28

Максимум

1.31

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+132.56% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-21M 82M
Предишно отваряне	4.34
Предишно затваряне	1.26

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.01.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15.01.2026 г., 00:00 ч. UTC

Печалби

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14.01.2026 г., 23:47 ч. UTC

Пазарно говорене

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14.01.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14.01.2026 г., 23:39 ч. UTC

Пазарно говорене

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14.01.2026 г., 23:32 ч. UTC

Пазарно говорене

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14.01.2026 г., 22:56 ч. UTC

Придобивния, сливания и поглъщания

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14.01.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14.01.2026 г., 22:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.01.2026 г., 22:17 ч. UTC

Пазарно говорене

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14.01.2026 г., 22:09 ч. UTC

Печалби

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14.01.2026 г., 22:08 ч. UTC

Печалби

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14.01.2026 г., 22:08 ч. UTC

Печалби

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14.01.2026 г., 21:53 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14.01.2026 г., 21:53 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14.01.2026 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Announces Positive Profit Alert for 2025

14.01.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Citigroup Acting as Financial Advisor to WuXi XDC

14.01.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC: Aims to Keep Listing Status of BioDlink

14.01.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

14.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

14.01.2026 г., 21:49 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14.01.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14.01.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Makes Cash Offer for BioDlink International

14.01.2026 г., 21:13 ч. UTC

Пазарно говорене

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14.01.2026 г., 20:30 ч. UTC

Пазарно говорене

Печалби

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14.01.2026 г., 20:13 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14.01.2026 г., 20:08 ч. UTC

Пазарно говорене

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14.01.2026 г., 19:33 ч. UTC

Пазарно говорене

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14.01.2026 г., 19:06 ч. UTC

Пазарно говорене

Печалби

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

132.56% нагоре

12-месечна прогноза

Среден 3 USD 132.56%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.